Adrian Field

Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt.

A.C.N. 142 916 970 Pty Ltd. provides management and operational workforce improvement solutions. It offers end-to-end managed service solution from initial advice on workforce strategy through to implementation of transformation agenda including the ongoing operational management of workforce. The company was founded by Adrian Field, Joe Caporale and Bob de Boer in April 2010 and is headquartered in Melbourne, Australia.

A.C.N. 142 916 970 Pty Ltd. provides management and operational workforce improvement solutions. It offers end-to-end managed service solution from initial advice on workforce strategy through to implementation of transformation agenda including the ongoing operational management of workforce. The company was founded by Adrian Field, Joe Caporale and Bob de Boer in April 2010 and is headquartered in Melbourne, Australia.

A.C.N. 142 916 970 Pty Ltd. provides management and operational workforce improvement solutions. It offers end-to-end managed service solution from initial advice on workforce strategy through to implementation of transformation agenda including the ongoing operational management of workforce. The company was founded by Adrian Field, Joe Caporale and Bob de Boer in April 2010 and is headquartered in Melbourne, Australia.

A.C.N. 142 916 970 Pty Ltd. provides management and operational workforce improvement solutions. It offers end-to-end managed service solution from initial advice on workforce strategy through to implementation of transformation agenda including the ongoing operational management of workforce. The company was founded by Adrian Field, Joe Caporale and Bob de Boer in April 2010 and is headquartered in Melbourne, Australia.

Perscitus Advisers Ltd (Perscitus Advisers) is a private equity firm founded in 2014 by Jon Moulton. The firm is headquartered in London, United Kingdom.

Perscitus Advisers Ltd (Perscitus Advisers) is a private equity firm founded in 2014 by Jon Moulton. The firm is headquartered in London, United Kingdom.

Perscitus Advisers Ltd (Perscitus Advisers) is a private equity firm founded in 2014 by Jon Moulton. The firm is headquartered in London, United Kingdom.

Perscitus Advisers Ltd (Perscitus Advisers) is a private equity firm founded in 2014 by Jon Moulton. The firm is headquartered in London, United Kingdom.

Perscitus Advisers Ltd (Perscitus Advisers) is a private equity firm founded in 2014 by Jon Moulton. The firm is headquartered in London, United Kingdom.

Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt.